CN107207599A - 具有增强的抑制性质的抗trka抗体及其衍生物用于治疗骨相关疼痛 - Google Patents

具有增强的抑制性质的抗trka抗体及其衍生物用于治疗骨相关疼痛 Download PDF

Info

Publication number
CN107207599A
CN107207599A CN201580075478.3A CN201580075478A CN107207599A CN 107207599 A CN107207599 A CN 107207599A CN 201580075478 A CN201580075478 A CN 201580075478A CN 107207599 A CN107207599 A CN 107207599A
Authority
CN
China
Prior art keywords
antibody
trka
pain
humanization
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201580075478.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·沃姆斯利
S·K·迪贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/562,297 external-priority patent/US20150183885A1/en
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of CN107207599A publication Critical patent/CN107207599A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
CN201580075478.3A 2014-12-05 2015-12-07 具有增强的抑制性质的抗trka抗体及其衍生物用于治疗骨相关疼痛 Withdrawn CN107207599A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/562,297 US20150183885A1 (en) 2012-06-08 2014-12-05 Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
US14/562,297 2014-12-05
EP15165107.2 2015-04-24
EP15165107 2015-04-24
PCT/EP2015/078875 WO2016087677A1 (fr) 2014-12-05 2015-12-07 Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses

Publications (1)

Publication Number Publication Date
CN107207599A true CN107207599A (zh) 2017-09-26

Family

ID=54838344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580075478.3A Withdrawn CN107207599A (zh) 2014-12-05 2015-12-07 具有增强的抑制性质的抗trka抗体及其衍生物用于治疗骨相关疼痛

Country Status (7)

Country Link
EP (1) EP3227334A1 (fr)
JP (1) JP2018505853A (fr)
CN (1) CN107207599A (fr)
CA (1) CA2969940A1 (fr)
HK (1) HK1244012A1 (fr)
MA (1) MA41097A (fr)
WO (1) WO2016087677A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010978A (zh) * 2019-05-30 2020-12-01 广东东阳光药业有限公司 TrkA的抗体及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327963A (zh) 2016-11-21 2023-06-27 济世-伊沃泰克生物制品有限公司 一种眼科制剂及其用途
JP7183268B2 (ja) * 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
AR114110A1 (es) * 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
WO2023125477A1 (fr) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited Anticorps trka et son application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073344A2 (fr) * 1999-05-26 2000-12-07 Lay Line Genomics Spa Anticorps monoclonaux et derives synthetiques et biotechnologiques de ceux-ci faisant office de molecules antagonistes du facteur ngf
CN101724070A (zh) * 2003-12-24 2010-06-09 雷莱恩基因组股份公司 人源化抗-ngf抗体
US7807162B2 (en) * 2005-05-20 2010-10-05 Ablynx N.V. Single domain VHH antibodies against von Willebrand factor
CN101939337A (zh) * 2008-02-04 2011-01-05 雷莱恩基因组有限公司 抗trka抗体及其衍生物
WO2013183032A2 (fr) * 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anticorps anti-trka ayant des propriétés inhibitrices améliorées et dérivés associés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
WO2012075340A2 (fr) * 2010-12-01 2012-06-07 Alderbio Holdings Llc Compositions anti-ngf et leur utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073344A2 (fr) * 1999-05-26 2000-12-07 Lay Line Genomics Spa Anticorps monoclonaux et derives synthetiques et biotechnologiques de ceux-ci faisant office de molecules antagonistes du facteur ngf
CN101724070A (zh) * 2003-12-24 2010-06-09 雷莱恩基因组股份公司 人源化抗-ngf抗体
US7807162B2 (en) * 2005-05-20 2010-10-05 Ablynx N.V. Single domain VHH antibodies against von Willebrand factor
CN101939337A (zh) * 2008-02-04 2011-01-05 雷莱恩基因组有限公司 抗trka抗体及其衍生物
WO2013183032A2 (fr) * 2012-06-08 2013-12-12 Glenmark Pharmaceuticals S.A. Anticorps anti-trka ayant des propriétés inhibitrices améliorées et dérivés associés
CN104520330A (zh) * 2012-06-08 2015-04-15 格兰马克药品股份有限公司 具有氨基酸取代的人源化抗TrkA抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GHILARDI J R 等: "Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers", 《BONE》 *
HONGO JS等: "antibody binding regions on human nerve growth factor identified by homolog and alanine-scanning mutagenesis", 《HYBRIDOMA》 *
KYLE G. HALVORSON 等: "A Blocking Antibody to Nerve Growth Factor Attenuates Skeletal Pain Induced by Prostate Tumor Cells Growing in Bone", 《CANCER RES》 *
LABRIJN AF 等: "Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo", 《NATURE BIOTECHNOLOGY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112010978A (zh) * 2019-05-30 2020-12-01 广东东阳光药业有限公司 TrkA的抗体及其应用
WO2020238998A1 (fr) * 2019-05-30 2020-12-03 Sunshine Lake Pharma Co., Ltd. Anticorps anti-trka et leurs utilisations
CN114230663A (zh) * 2019-05-30 2022-03-25 广东东阳光药业有限公司 TrkA的抗体及其应用

Also Published As

Publication number Publication date
EP3227334A1 (fr) 2017-10-11
HK1244012A1 (zh) 2018-07-27
CA2969940A1 (fr) 2016-06-09
JP2018505853A (ja) 2018-03-01
MA41097A (fr) 2017-10-10
WO2016087677A1 (fr) 2016-06-09

Similar Documents

Publication Publication Date Title
EP2859019B1 (fr) Anticorps humanisés anti-trka avec substitutions d'acides aminés
CN102597002B (zh) 离子通道的抗体
CN105073775B (zh) 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
CN107207599A (zh) 具有增强的抑制性质的抗trka抗体及其衍生物用于治疗骨相关疼痛
CN102781963B (zh) 功能修饰性NAv1.7抗体
CN103739711B (zh) 抗人il-4受体的高亲和性人抗体
CN105377237B (zh) 使免疫反应的调节与生物药品的给药相关的方法和制剂
CN103717263A (zh) 结合ox40的抗体及其用途
CN107074962A (zh) 针对her2表位的单克隆抗体及其使用方法
CN102844332A (zh) 呈pH依赖性抗原结合的抗体
CN106659790A (zh) 抗cdh6抗体药物缀合物
CN109929035A (zh) 抗人ngf抗体及其制备方法和用途
CN106459190A (zh) 用于治疗疼痛的化合物和方法
US20220267451A1 (en) Compositions and methods for treatment of thyroid eye disease
BR112020022035A2 (pt) proteínas de ligação de receptor de canabinoide tipo 1 (cb1) e usos das mesmas
EP3647323A1 (fr) Anticorps anti-gitr, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée
US20160319027A1 (en) Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
US20170362327A1 (en) Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain
WO2023125490A1 (fr) Anticorps anti-trka et application de celui-ci
CN117460749A (zh) 抗EGFRvIII抗体药物缀合物及其用途
WO2023122714A2 (fr) Compositions et procédés pour le traitement d'une maladie oculaire thyroïdienne
WO2023133486A2 (fr) Compositions et méthodes pour le traitement d'une maladie oculaire thyroïdienne
WO2023133485A2 (fr) Compositions et méthodes pour le traitement d'une maladie oculaire thyroïdienne
KR20240024061A (ko) 항-EGFRvIII 항체 약물 접합체 및 이의 용도
OA17182A (en) Humanized anti-TrkA antibodies with amino acid substitutions.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1244012

Country of ref document: HK

CB02 Change of applicant information

Address after: La Chaux-de-Fonds

Applicant after: IKONOS Science

Address before: La Chaux-de-Fonds

Applicant before: Glenmark Pharmaceuticals S. A.

CB02 Change of applicant information
WW01 Invention patent application withdrawn after publication

Application publication date: 20170926

WW01 Invention patent application withdrawn after publication